The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626001050347p
Ethics application status
Help: Ethics application status
Submitted, not yet approved
Date submitted
Help: Date submitted
5/08/2026
Date registered
Help: Date registered
26/08/2026
Date last updated
Help: Date last updated
26/08/2026
Date data sharing statement initially provided
Help: Data sharing statement date
26/08/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
A study in healthy volunteers to compare how much SOR102 gets into the blood and how much passes out in the stool when taken as a capsule or as a tablet, and when taken with food
Scientific title
A Multiple-Dose, Open-Label, Sequential, Formulation Comparability Bridging Study to Compare the Serum Levels and Fecal Recovery of a Capsule and Tablet Formulation of SOR102 and to Assess the Serum Levels and Fecal Recovery of SOR102 Dosed Under Nonfasted Conditions in Healthy Volunteers
Additional trial identifiers [1] 318083 0
SOR102-103
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Inflammatory bowel disease 343108 0
Condition category
Condition code
Oral and Gastrointestinal 339200 339200 0 0
Inflammatory bowel disease

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Approximately 16 healthy men or women will be enrolled in this study. There will be three periods in the study study.

- Period 1: In Period 1, participants will receive the SOR102 capsule formulation at a dose of 675mg given orally twice a day under fasted conditions for 7 days, Participants will receive their morning and evening dose of SOR102 following a fast of at least 2 hours and will be required to continue to fast from food for a minimum of 1 hour following administration of SOR102 . With the exception of the 240 mL of water taken with the dose, participants will not be allowed fluids from 2 hours prior to until 1 hour after dosing. Following completion of 7 days of SOR102 dosing, participants will be discharged from the Clinical Research Unit on Day 8 for the first 7 day washout period.
- Period 2: Following the washout period, participants will return to the Clinical Research Unit for Period 2 where they will receive the SOR102 tablet formulation at a dose of 600mg given orally twice a day under fasted conditions for 7 days. Participants will receive their morning and evening dose of SOR102 following a fast of at least 2 hours and will be required to continue to fast from food for a minimum of 1 hour following administration of SOR102 . With the exception of the 240 mL of water taken with the dose, participants will not be allowed fluids from 2 hours prior to until 1 hour after dosing. Following completion of 7 days of SOR102 dosing, participants will be discharged from the Clinical Research Unit on Day 8 for the second 7 day washout period.
- Period 3: Following the washout period, participants will return to the Clinical Research Unit for Period 3 where they will receive the SOR102 tablet formulation at a dose of 600mg given orally twice a day under nonfasted conditions for 7 days. Each dose of SOR102 will be taken 15 minutes after completion of a standard non-high fat meal. The meal will have about 45 to 65 grams of carbohydrates, 25 to 40 grams of protein, and 10 to 15 grams of fat. Following completion of 7 days of SOR102 dosing, participants will be discharged from the Clinical Research Unit on Day 8. Participants will return to the Clinical Research Unit for an ambulatory follow-up visit 1 week later.
Intervention code [1] 334967 0
Treatment: Drugs
Description of the comparator or control
No control group
Control group
Uncontrolled

Outcomes
Primary outcome [1] 346440 0
Serum levels of SOR102 capsules taken fasted orally BID in healthy adult participants over the course of 7 days.
Timepoint [1] 346440 0
Blood will be collected pre-dose on Day 1 and on Day 8 (post first dose) prior to discharge.
Primary outcome [2] 346441 0
Fecal recovery of SOR102 capsules taken fasted orally BID in healthy adult participants over the course of 7 days.
Timepoint [2] 346441 0
In each period, all stools will be collected from the time of admission to the Clinical Research Unit through discharge on Day 8 (post the first dose for the period)
Primary outcome [3] 346558 0
Fecal recovery of SOR102 tablets taken fasted orally BID in healthy adult participants over the course of 7 days.
Timepoint [3] 346558 0
All stools will be collected from the time of admission to the Clinical Research Unit through discharge on Day 8 (post the first dose for the period)
Secondary outcome [1] 465850 0
Assess the composite safety and tolerability of SOR102 in healthy adult participants.
Timepoint [1] 465850 0
Treatment-emergent adverse events will be collected from the time of signing the informed consent form through the follow-up visit. Physical examinations will be performed at screening and at the follow-up visit with symptom directed physical examinations performed at Day -1, Day 4 and Day 8 (post first dose) in each Period, Vital signs will be collected at screening, in each Period once daily on Day -1 through Day 8 (post first dose) in each period, and at the follow-up visit (Day 43 post the Period 1 first dose). ECGs will be collected at screening and at the follow-up visit (Day 43 post the Period 1 first dose). Clinical laboratory assessments of blood and urine will be collected at screening, on Day -1 and Day 8 (post first dose) in Period 1, on Day -1, Day 4 and Day 8 (post first dose) in Period 2 and Period 3, and at the follow-up visit (Day 43 post the Period 1 first dose).
Secondary outcome [2] 466378 0
Primary outcome: Serum levels of SOR102 tablets taken fasted orally BID in healthy adult participants over the course of 7 days.
Timepoint [2] 466378 0
Blood will be collected pre-dose on Day 1 and on Day 8 (post first dose) prior to discharge.
Secondary outcome [3] 466379 0
Primary outcome: Serum levels of SOR102 tablets taken nonfasted orally BID in healthy adult participants over the course of 7 days.
Timepoint [3] 466379 0
Blood will be collected pre-dose on Day 1 and on Day 8 (post first dose) prior to discharge. A final sample will be collected at the Follow-Up visit (Day 43 post the Period 1 first dose).
Secondary outcome [4] 466380 0
Primary outcome: Fecal recovery of SOR102 tablets taken nonfasted orally BID in healthy adult participants over the course of 7 days.
Timepoint [4] 466380 0
All stools will be collected from the time of admission to the Clinical Research Unit through discharge on Day 8 (post the first dose for the period)

Eligibility
Key inclusion criteria
Body weight at least 50kg and no more than 110kg and body mass index within the range 18-35 kg/m2 (inclusive)
Deemed healthy as determined by medical history, physical examination, vital sign measurements, ECG, and laboratory safety tests
No clinically relevant abnormalities in clinical laboratory evaluations
Normal bowel habits
Not lactating or pregnant
Capable of giving signed informed consent
Agrees to be available for all study visits and cooperates fully with the requirements of the study protocol, including the schedule of assessments



Minimum age
18 Years
Maximum age
65 Years
Sex
Both males and females
Healthy volunteers
Yes
Key exclusion criteria
Clinically relevant history of physical or mental health abnormalities that might interfere with the study
Clinically relevant abnormal laboratory results, 12-lead ECG and vital signs, or physical findings
History or clinical evidence of any disease and/or existence of any surgical or medical condition which might interfere with the study drug.
History of latent or active tuberculosis.
Positive (or 2 indeterminate) QuantiFERON test results.
Positive test for hepatitis B surface antigen, anti-hepatitis C antibody or human immunodeficiency virus I and II.
Positive urine test for drugs of abuse or alcohol breath test
Taken part in a clinical study and has received a medication or a new chemical entity within 30 days or 5 half-lives (whichever is longer) prior to dosing of current study medication.
Use or intended use of any prohibited medications
Known history of heart disease.
History of significant GI disease, including GI motility disorders.
History of abnormal bowel habits (e.g., a history of chronic constipation or chronic diarrhea).
Previous surgery to the GI tract with the exception of appendectomy and hernia repair
Systolic BP (SBP) of 160 mmHg or diastolic BP (DBP) of 95 mmHg
Orthostatic intolerance at Screening
Participant is unlikely to co-operate with the requirements of the study, in the opinion of the Investigator.




Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Crossover
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
SA
Recruitment hospital [1] 29949 0
CMAX Clinical Research Pty Ltd - Adelaide
Recruitment postcode(s) [1] 46312 0
5000 - Adelaide

Funding & Sponsors
Funding source category [1] 322642 0
Commercial sector/Industry
Name [1] 322642 0
Sorriso Pharmaceuticals Australia, Pty. Ltd
Country [1] 322642 0
Australia
Primary sponsor type
Commercial sector/Industry
Name
Sorriso Pharmaceuticals Australia, Pty. Ltd
Address
Country
Australia
Secondary sponsor category [1] 325567 0
None
Name [1] 325567 0
Address [1] 325567 0
Country [1] 325567 0

Ethics approval
Ethics application status
Submitted, not yet approved
Ethics committee name [1] 321100 0
Bellberry Human Research Ethics Committee G
Ethics committee address [1] 321100 0
Ethics committee country [1] 321100 0
Australia
Date submitted for ethics approval [1] 321100 0
04/08/2026
Approval date [1] 321100 0
Ethics approval number [1] 321100 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 152666 0
Dr Jessica Gehlert
Address 152666 0
CMAX Clinical Research Pty Ltd, Ground Floor, 21-24 North Terrace, Adelaide, South Australia 5000
Country 152666 0
Australia
Phone 152666 0
+61 0421311443
Fax 152666 0
Email 152666 0
Contact person for public queries
Name 152667 0
CMAX Clinical Research Pty Ltd
Address 152667 0
CMAX Clinical Research Pty Ltd, Ground Floor, 21-24 North Terrace, Adelaide, South Australia 5000
Country 152667 0
Australia
Phone 152667 0
+61 8 7088 7900
Fax 152667 0
Email 152667 0
Contact person for scientific queries
Name 152668 0
CMAX Clinical Research Pty Ltd
Address 152668 0
CMAX Clinical Research Pty Ltd, Ground Floor, 21-24 North Terrace, Adelaide, South Australia 5000
Country 152668 0
Australia
Phone 152668 0
+61 8 7088 7900
Fax 152668 0
Email 152668 0

Data sharing statement
Will the study consider sharing individual participant data?
No
No IPD sharing reason/comment: Only aggregate participant data will be available from this study



What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.